Sosei Heptares Idorsia Japan APAC Acquisition 2023

Sosei Heptares announced the acquisition of Idorsia's operations in Japan and APAC regions (excluding China) in July 2023. The deal combines the company's world-leading GPCR drug discovery platform with Idorsia's clinical development capabilities and high-margin pharmaceutical sales business. The acquisition advances Sosei's mission to deliver life-changing medicines to patients in Japan and APAC markets.